Fitch Ratings upgraded its credit grade on both Bausch + Lomb Corp. and its parent company Bausch Health Cos., but said the ...

Bausch + Lomb has gotten torched over the last six months - since October 2024, its stock price has dropped 41.5% to $12.06 ...

Bausch + Lomb issued the recall after the company received reports of toxic anterior segment syndrome, or an inflammatory ...

The eye health company Bausch + Lomb announced on Monday that it is recalling several of its intraocular lenses due to safety ...

NEW YORK CITY, NY / ACCESS Newswire / April 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Bausch + Lomb, a leading global eye health company, announced a voluntary recall of its Envista Aspire, Envista Envy and ...

Bausch + Lomb is recalling intraocular lenses (IOLs) on its enVista platform. This action was taken after the company ...

Bausch + Lomb shares tumbled in intraday trading Friday, a day after the eye-care company announced a "voluntary recall" of some of its intraocular lenses due to safety concerns.

Most cases of TASS can be treated with steroids within a few days, although severe cases can lead to permanent damage to the cornea, the clear, outermost layer of the eye. Severe cases can also lead ...

HealthDay News — Bausch + Lomb has announced a voluntary recall of intraocular lenses on its enVista platform due to the potential for an acute postoperative inflammatory reaction.

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It ...